Contact

• Evaluation of various diagnostic, clinical, biological, genetic, and imaging parameters to improve the prediction of prostate cancer.

• Mischinger Johannes

• Early detection of prostate cancer based on clinical variables, morphological imaging, and molecular markers
• FWF-KLIF (KLI 914-B)
• Retrospective comparison of MRI-TRUS fusion biopsy with systematic TRUS biopsy for prostate cancer detection, correlation of qualitative (PI-RADS) and quantitative (texture analysis) MRI image features with histological results, and evaluation of the collected data in a prospective cohort to improve the PI-RADS classification.
• Combining MRI-TRUS fusion and systematic TRUS prostate biopsy for the diagnosis of prostate cancer—biopsy-naïve vs. prior-negative biopsy patients.
• Nomogram to omit systematic biopsy in mpMRI-positive patients
• Information-seeking behavior and decision-making regarding open vs. robot-assisted radical prostatectomy
• Clinical characteristics of incidental prostate cancer following HoLEP and TUR-P (thesis)

• Zurl Hanna

• Department of Radiology, Medical University of Graz
• D & F Institute for Diagnosis and Research in Human Genetics, Medical University of Graz
• D & F Institute for Pathology, Medical University of Graz
• Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz
• Institute for Medical Informatics, Statistics, and Documentation, Medical University of Graz
• Department of Urology, Leipzig University of Technology, Germany

• Mischinger Johannes
• Seles Maximilian
• Hutterer Georg
• Zigeuner Richard

• Validation of Two Subclassifications of T1 Urothelial Carcinoma of the Bladder and Evaluation of the Prognostic Value of the Expression Profile of B7-H3 and B7-H4
  Project Leader: Johannes Mischinger.
• By analyzing the expression patterns of two proteins and validating two recently developed risk assessment models in a large cohort of patients with pT1 urothelial carcinoma of the bladder treated at the University Clinic for Urology, the aim is to significantly improve risk assessment regarding recurrence, progression, cancer-specific and overall survival for the affected patients. Additionally, this research project will retrospectively analyze patients’ response to intravesical instillation therapy (BCG).
• Retrospective comparison of the recurrence rate of non-muscle-invasive bladder cancer following primary transurethral resection of the bladder under general anesthesia versus spinal anesthesia, taking into account the Charlson Comorbidity Index.
  Project Leader: Johannes Mischinger
• Protocol for the Individual Patient Data Validation of the Definition of BCG Failure/BCG Unresponsive in Patients with Non-muscle Invasive Urothelial Carcinoma of the Bladder: an international multi-center retrospective study.
  Project leaders: Richard Zigeuner, Maximilian Seles.
• The primary objective of this international multicenter study is to validate the prognostic value of various existing definitions of treatment failure (BCG failure/BCG unresponsiveness) in intravesical instillation therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder
• Oncologic outcome analysis after transurethral bladder resection associated with general vs. spinal anesthesia and in relation to comorbidities
  Project leaders: Georg C. Hutterer
• Clinically significant tumor histology in elective transurethral resection of the bladder (thesis)

• Diagnostic and Research Institute for Pathology, Medical University of Graz, Sebastian Mannweiler
• EAU Non-Muscle-Invasive Bladder Cancer Guidelines Panel
• M. Babjuk, Prague (CZ); M. Burger, Regensburg (DE); E. M. Compérat, Paris (FR); P. Gontero, Turin (IT); H. Mostafid, Guilford (UK); J. Palou Redorta, Barcelona (ES); M. Rouprêt, Paris (FR); S. F. Shariat, Vienna (AT); R. Sylvester, Brussels (BE); B. van Rhijn, Amsterdam (NL); R. Zigeuner, Graz (AT)

• Thesis: Joanna Gleissner and Dissertation: Stephanie Schöpfer-Schwab: “Validation of Two Subclassifications of T1 Urothelial Carcinoma of the Bladder and Evaluation of the Prognostic Value of the Expression Profile of B7-H3 and B7-H4.”
• Thesis: Stefan Andlar: “Retrospective comparison of the recurrence rate of non-muscle-invasive bladder cancer after primary transurethral resection of the bladder under general anesthesia versus spinal anesthesia, taking into account the Charlson Comorbidity Index”

• Basic research in urological oncology

• Hutterer Georg
• Seles Maximilian

• Identification and Characterization of the Long Non-coding RNA PANTR1 in Clear Cell Renal Cell Carcinoma
• Investigation of non-coding RNAs (segments of the human genome that are translated but not transcribed) and their epigenetic regulatory properties in clear cell renal cell carcinoma. Conducting analyses of genetic databases and in vitro cell experiments to investigate the potential tumor-promoting/suppressing properties of the long non-coding RNA PANTR1 in this tumor entity.
• The influence of perioperative administration, transfusion volume, and storage age of red blood cell concentrates on clinical outcomes in patients with non-metastatic renal cell carcinoma
• Improved overall survival of patients with metastatic renal cell carcinoma in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-world Austrian population-based study comprising three decades of follow-up
• Evaluation of the potential prognostic value of the preoperatively assessed eosinophil granulocyte count regarding overall survival in non-metastatic clear cell renal cell carcinoma
• Evaluation of the potential prognostic value of preoperatively assessed hyponatremia regarding survival outcomes in non-metastatic clear cell renal cell carcinoma

• Division of Oncology, Department for Internal Medicine: Martin Pichler, Head of the Research Unit “Non-Coding RNAs and Genome Editing in Cancer”

Penile cancer is a rare malignant tumor that affects less than 1% of men in Europe. Because of its rarity, treatment should be provided at centers with specialized expertise. There is also potential for research in the areas of prevention and early detection.

• Establishing comprehensive expertise on penile cancer in clinical practice, research, and teaching
• Development of a prospective penile cancer database

• Seles Maximilian
• Hutterer Georg

• Next-generation sequencing of all penile cancers diagnosed since 1986 to evaluate potential therapeutic targets and biomarkers
• Adherence to the EAU guideline recommendations for systemic chemotherapy in penile cancer: results of the E-PROPS study group survey.
  The aim of this international multicenter study (European PROspective Penile Cancer Study) is to validate adherence to the European Association of Urology’s guidelines regarding chemotherapy recommendations for the treatment of advanced penile cancer by 45 urology hospitals in four countries (Germany, Austria, Switzerland, and Italy).
• Does the identification of a minimum number of cases correlate with better adherence to international guidelines regarding the treatment of penile cancer? Survey results of the European PROspective Penile Cancer Study (E-PROPS).
• The aim of this part of the international multicenter study (European PROspective Penile Cancer Study) is to answer the question of whether the number of patients treated for advanced penile cancer at the participating study centers correlates with adherence to the European Association of Urology’s chemotherapy guidelines.

• Prof. Sigrid Regauer, Ph.D., Mikhail Ermakov, Ph.D., and Karl Kashofer, Ph.D. (Diagnostic and Research Institute for Pathology, Medical University of Graz)
• Prof. Matthias May, Department of Urology, Barmherzige Brüder Hospital, St. Elisabeth Hospital Straubing, Germany

• Stephanie Schöpfer-Schwab
• Khayati Souhail